246 related articles for article (PubMed ID: 15723074)
1. EIF2B5 mutations compromise GFAP+ astrocyte generation in vanishing white matter leukodystrophy.
Dietrich J; Lacagnina M; Gass D; Richfield E; Mayer-Pröschel M; Noble M; Torres C; Pröschel C
Nat Med; 2005 Mar; 11(3):277-83. PubMed ID: 15723074
[TBL] [Abstract][Full Text] [Related]
2. Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter.
Leegwater PA; Vermeulen G; Könst AA; Naidu S; Mulders J; Visser A; Kersbergen P; Mobach D; Fonds D; van Berkel CG; Lemmers RJ; Frants RR; Oudejans CB; Schutgens RB; Pronk JC; van der Knaap MS
Nat Genet; 2001 Dec; 29(4):383-8. PubMed ID: 11704758
[TBL] [Abstract][Full Text] [Related]
3. Identification of ten novel mutations in patients with eIF2B-related disorders.
Ohlenbusch A; Henneke M; Brockmann K; Goerg M; Hanefeld F; Kohlschütter A; Gärtner J
Hum Mutat; 2005 Apr; 25(4):411. PubMed ID: 15776425
[TBL] [Abstract][Full Text] [Related]
4. Glial pathology in a novel spontaneous mutant mouse of the Eif2b5 gene: a vanishing white matter disease model.
Terumitsu-Tsujita M; Kitaura H; Miura I; Kiyama Y; Goto F; Muraki Y; Ominato S; Hara N; Simankova A; Bizen N; Kashiwagi K; Ito T; Toyoshima Y; Kakita A; Manabe T; Wakana S; Takebayashi H; Igarashi H
J Neurochem; 2020 Jul; 154(1):25-40. PubMed ID: 31587290
[TBL] [Abstract][Full Text] [Related]
5. Astrocytes are central in the pathomechanisms of vanishing white matter.
Dooves S; Bugiani M; Postma NL; Polder E; Land N; Horan ST; van Deijk AL; van de Kreeke A; Jacobs G; Vuong C; Klooster J; Kamermans M; Wortel J; Loos M; Wisse LE; Scheper GC; Abbink TE; Heine VM; van der Knaap MS
J Clin Invest; 2016 Apr; 126(4):1512-24. PubMed ID: 26974157
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of safety and early efficacy of AAV gene therapy in mouse models of vanishing white matter disease.
Herstine JA; Chang PK; Chornyy S; Stevenson TJ; Sunshine AC; Nokhrina K; Rediger J; Wentz J; Vetter TA; Scholl E; Holaway C; Pyne NK; Bratasz A; Yeoh S; Flanigan KM; Bonkowsky JL; Bradbury AM
Mol Ther; 2024 Jun; 32(6):1701-1720. PubMed ID: 38549375
[TBL] [Abstract][Full Text] [Related]
7. Mutations linked to leukoencephalopathy with vanishing white matter impair the function of the eukaryotic initiation factor 2B complex in diverse ways.
Li W; Wang X; Van Der Knaap MS; Proud CG
Mol Cell Biol; 2004 Apr; 24(8):3295-306. PubMed ID: 15060152
[TBL] [Abstract][Full Text] [Related]
8. Mutant eIF2B leads to impaired mitochondrial oxidative phosphorylation in vanishing white matter disease.
Raini G; Sharet R; Herrero M; Atzmon A; Shenoy A; Geiger T; Elroy-Stein O
J Neurochem; 2017 Jun; 141(5):694-707. PubMed ID: 28306143
[TBL] [Abstract][Full Text] [Related]
9. Poor cerebral inflammatory response in eIF2B knock-in mice: implications for the aetiology of vanishing white matter disease.
Cabilly Y; Barbi M; Geva M; Marom L; Chetrit D; Ehrlich M; Elroy-Stein O
PLoS One; 2012; 7(10):e46715. PubMed ID: 23056417
[TBL] [Abstract][Full Text] [Related]
10. Vanishing white matter: deregulated integrated stress response as therapy target.
Abbink TEM; Wisse LE; Jaku E; Thiecke MJ; Voltolini-González D; Fritsen H; Bobeldijk S; Ter Braak TJ; Polder E; Postma NL; Bugiani M; Struijs EA; Verheijen M; Straat N; van der Sluis S; Thomas AAM; Molenaar D; van der Knaap MS
Ann Clin Transl Neurol; 2019 Aug; 6(8):1407-1422. PubMed ID: 31402619
[TBL] [Abstract][Full Text] [Related]
11. A mouse model for eukaryotic translation initiation factor 2B-leucodystrophy reveals abnormal development of brain white matter.
Geva M; Cabilly Y; Assaf Y; Mindroul N; Marom L; Raini G; Pinchasi D; Elroy-Stein O
Brain; 2010 Aug; 133(Pt 8):2448-61. PubMed ID: 20826436
[TBL] [Abstract][Full Text] [Related]
12. The spectrum of mutations for the diagnosis of vanishing white matter disease.
Scali O; Di Perri C; Federico A
Neurol Sci; 2006 Sep; 27(4):271-7. PubMed ID: 16998732
[TBL] [Abstract][Full Text] [Related]
13. Heightened stress response in primary fibroblasts expressing mutant eIF2B genes from CACH/VWM leukodystrophy patients.
Kantor L; Harding HP; Ron D; Schiffmann R; Kaneski CR; Kimball SR; Elroy-Stein O
Hum Genet; 2005 Oct; 118(1):99-106. PubMed ID: 16041584
[TBL] [Abstract][Full Text] [Related]
14. The Energy Status of Astrocytes Is the Achilles' Heel of eIF2B-Leukodystrophy.
Herrero M; Daw M; Atzmon A; Elroy-Stein O
Cells; 2021 Jul; 10(8):. PubMed ID: 34440627
[TBL] [Abstract][Full Text] [Related]
15. Infantile onset Vanishing White Matter disease associated with a novel EIF2B5 variant, remarkably long life span, severe epilepsy, and hypopituitarism.
Woody AL; Hsieh DT; McIver HK; Thomas LP; Rohena L
Am J Med Genet A; 2015 Apr; 167A(4):826-30. PubMed ID: 25758335
[TBL] [Abstract][Full Text] [Related]
16. Leucoencephalopathy with vanishing white matter may cause progressive myoclonus epilepsy.
Jansen AC; Andermann E; Niel F; Creveaux I; Boespflug-Tanguy O; Andermann F
Epilepsia; 2008 May; 49(5):910-3. PubMed ID: 18266750
[TBL] [Abstract][Full Text] [Related]
17. Vanishing white matter disease.
van der Knaap MS; Pronk JC; Scheper GC
Lancet Neurol; 2006 May; 5(5):413-23. PubMed ID: 16632312
[TBL] [Abstract][Full Text] [Related]
18. Leukoencephalopathy with vanishing white matter: a review.
Bugiani M; Boor I; Powers JM; Scheper GC; van der Knaap MS
J Neuropathol Exp Neurol; 2010 Oct; 69(10):987-96. PubMed ID: 20838246
[TBL] [Abstract][Full Text] [Related]
19. Ovarioleukodystrophy due to EIF2B5 mutations.
Ibitoye RT; Renowden SA; Faulkner HJ; Scolding NJ; Rice CM
Pract Neurol; 2016 Dec; 16(6):496-499. PubMed ID: 27651498
[TBL] [Abstract][Full Text] [Related]
20. The life and death of oligodendrocytes in vanishing white matter disease.
Van Haren K; van der Voorn JP; Peterson DR; van der Knaap MS; Powers JM
J Neuropathol Exp Neurol; 2004 Jun; 63(6):618-30. PubMed ID: 15217090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
